Literature DB >> 23278344

Reduction of medication costs after detoxification for medication-overuse headache.

Asif M Shah1, Lars Bendtsen, Peter Zeeberg, Rigmor H Jensen.   

Abstract

OBJECTIVE: To examine whether detoxifying patients with medication-overuse headache can reduce long-term medication costs.
BACKGROUND: Direct costs of medications in medication-overuse headache have been reported to be very high but have never been calculated on the basis of exact register data. Long-term economic savings obtained by detoxification have never been investigated.
METHODS: We conducted a registry-based observational retrospective follow-up study on 336 medication-overuse headache patients treated and discharged from the Danish Headache Center over a 2-year period. By means of the Danish Register of Medicinal Product Statistics, we collected information on the costs and use of prescription-only medication 1 year before admission and 1 year after discharge from Danish Headache Center.
RESULTS: The average medication costs per patient per year decreased with 24%, from US$971 before treatment to US$737 after (P = .001), and the average medication use decreased with 14.4% (P = .02). Savings were most pronounced for patients overusing triptans. In this group, the average medication costs per patient per year decreased with 43% (P < .001), while the average triptan use decreased with 38% (P < .001).
CONCLUSIONS: The study demonstrates that detoxification of medication-overuse headache at a tertiary headache center has a long-lasting effect on the medication costs and use, in particular among patients overusing triptans. The results may not be generalizable to all countries and may be sensitive to the costs of triptans.
© 2012 American Headache Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23278344     DOI: 10.1111/head.12031

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  7 in total

Review 1.  Medication-overuse headache: a perspective review.

Authors:  Maria Lurenda Westergaard; Signe Bruun Munksgaard; Lars Bendtsen; Rigmor Højland Jensen
Journal:  Ther Adv Drug Saf       Date:  2016-06-30

Review 2.  [Integrated headache care network. Kiel Migraine and Headache Center and German National Headache Treatment Network].

Authors:  H Göbel; K Heinze-Kuhn; I Petersen; A Göbel; A Heinze
Journal:  Schmerz       Date:  2013-04       Impact factor: 1.107

3.  [Classification and therapy of medication-overuse headache: impact of the third edition of the International Classification of Headache Disorders].

Authors:  H Göbel; K Heinze-Kuhn; I Petersen; C Göbel; A Göbel; A Heinze
Journal:  Schmerz       Date:  2014-04       Impact factor: 1.107

4.  Treatment of withdrawal headache in patients with medication overuse headache: a pilot study.

Authors:  Sabina Cevoli; Giulia Giannini; Valentina Favoni; Rossana Terlizzi; Elisa Sancisi; Marianna Nicodemo; Stefano Zanigni; Maria Letizia Bacchi Reggiani; Giulia Pierangeli; Pietro Cortelli
Journal:  J Headache Pain       Date:  2017-05-12       Impact factor: 7.277

5.  Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine.

Authors:  Janet H Ford; Shonda A Foster; Virginia L Stauffer; Dustin D Ruff; Sheena K Aurora; Jan Versijpt
Journal:  Patient Prefer Adherence       Date:  2018-11-13       Impact factor: 2.711

6.  Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache.

Authors:  Jill C Rau; Edita Navratilova; Janice Oyarzo; Kirk W Johnson; Sheena K Aurora; Todd J Schwedt; David W Dodick; Frank Porreca
Journal:  Cephalalgia       Date:  2020-06-24       Impact factor: 6.292

7.  Health and quality of life in patients with medication overuse headache syndrome after standardized inpatient rehabilitation: A cross-sectional pilot study.

Authors:  Thomas Benz; Achim Nüssle; Susanne Lehmann; Andreas R Gantenbein; Peter S Sándor; Achim Elfering; André G Aeschlimann; Felix Angst
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.